HOUSTON, Texas, June 5, 2026
Eos SENOLYTIX, Inc. presented new preclinical findings for its lead MitoXcel™ geropeptide candidate PTC-2105 at the Sachs 2nd Annual Obesity & Cardiometabolic Innovation Forum, showcasing significant improvements in body composition, physical function, metabolic health, and survival in aging animal models. The data highlighted the potential of PTC-2105 to address key biological mechanisms of aging by targeting mitochondrial dysfunction and senescent cells, offering a differentiated approach compared with current obesity therapies focused primarily on weight reduction.
PTC-2105 Demonstrates Improved Body Composition
Preclinical studies presented by the company showed that PTC-2105 delivered substantial reductions in fat mass while simultaneously increasing lean muscle mass, a combination rarely observed with currently available obesity treatments. Unlike GLP-1 receptor agonists, which often result in both fat and lean mass loss, PTC-2105 improved body composition without reducing food intake and demonstrated sustained benefits after treatment discontinuation. The therapy also significantly reduced visceral fat accumulation and enhanced physical performance in naturally aging animal models, supporting its potential application in sarcopenia, sarcopenic obesity, and other age-related disorders.
Broad Healthspan Benefits Observed
Beyond body composition improvements, PTC-2105 demonstrated positive effects across multiple biological systems associated with aging. The therapy selectively reduced senescent immune cells linked to age-related decline, resulting in improvements in cognitive performance and immune system function. Researchers also observed prevention of age-related weight gain and protection against the severe physical deterioration commonly seen during advanced aging. The company reported that animals treated with PTC-2105 maintained healthier muscle mass, physical activity, and overall condition compared with untreated controls and animals previously exposed to semaglutide-based treatment cycles.
Advertisement
Survival Data Support Gerotherapeutic Potential
One of the most notable findings presented was the significant improvement in both overall survival and cancer-specific survival among treated animals. According to the company, long-term studies demonstrated a statistically significant survival advantage after 66 weeks of treatment. At 146 weeks of age, 40% of animals receiving PTC-2105 remained alive, active, and healthy, while all saline-treated control animals had died by 137 weeks. Eos SENOLYTIX believes these results support the concept that targeting mitochondrial aging mechanisms may extend healthspan and lifespan simultaneously. The company is advancing its MitoXcel™ platform as a potential therapeutic approach for a broad range of age-related diseases, including metabolic, neurodegenerative, cognitive, and mitochondrial disorders. The presentation further strengthens the development rationale for PTC-2105 as Eos prepares for its planned merger with Pulmatrix, Inc., which is expected to support future clinical advancement of the program.
Source: Eos SENOLYTIX, press release
